Institutional members access full text with Ovid®

Share this article on:

Diagnostic Approach to Myeloneuropathy

Goodman, Brent P. MD

doi: 10.1212/01.CON.0000403793.13291.f3
Review Articles

ABSTRACT Disorders that concomitantly affect the spinal cord and peripheral nerves can be characterized as myeloneuropathies. Such conditions can be broadly categorized as metabolic, inflammatory, infectious, or hereditary disorders. Because these disorders may present with predominantly myelopathic or peripheral neuropathic signs and symptoms, a careful neurologic examination and a thoughtful diagnostic evaluation are necessary to establish a diagnosis of myeloneuropathy. This article outlines an approach to the identification, evaluation, and treatment of myeloneuropathy.

Address correspondence to Dr Brent P. Goodman, Mayo Clinic, Department of Neurology, 13400 E. Shea Boulevard, Scottsdale, AZ 85259, goodman.brent@mayo.edu.

Relationship Disclosure: Dr Goodman reports no disclosure.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Goodman discusses the unlabeled or investigational use of azathioprine, thalidomide, chloroquine, hydroxychloroquine, intravenous immunoglobulin, plasma exchange, corticosteroids, methotrexate, infliximab, cyclophosphamide, and glyceryl trioleate-glyceryl trierucate.

© 2011 American Academy of Neurology
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website